skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Eculizumab (Code C48386)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Eculizumab

Definition: A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)

NCI-GLOSS Definition: A monoclonal antibody used to prevent red blood cells from being destroyed in patients with paroxysmal nocturnal hemoglobinuria (PNH), a red blood cell disorder. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body. Eculizumab blocks a protein in the blood that causes the breakdown of red blood cells.

Label: Eculizumab

NCI Thesaurus Code: C48386 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1541483  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Immunoglobulin, Anti-(Human Complement C5 Alpha-Chain) (Human-Mouse Monoclonal 5G1.1 Heavy Chain), Disulfide with Human-Mouse Monoclonal 5G.1.1 Light Chain, Dimer
Monoclonal antibody 5G1.1

External Source Codes: 
CAS Registry Number 219685-50-4 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 415541
PDQ Open Trial Search ID 415541 (check for NCI PDQ open clinical trial info)
UMLS CUI C1541483

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Paroxysmal Nocturnal Hemoglobinuria
code C48386
Contributing_Source FDA
Legacy_Concept_Name Eculizumab
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom